q 2006 by Taylor & Francis Group, LLC - Developers

More documents

Recommendations

Info

Contributors Hamidreza Montazeri Aliabadi Department of Pharmacy and Pharmaceutical Sciences University of Alberta Edmonton, Alberta, Canada Christine Allen Department of Pharmaceutical Sciences and Department of Chemical Engineering and Applied Chemistry University of Toronto Toronto, Ontario, Canada Ashootosh V. Ambade Department of Chemistry University of Massachusetts at Amherst Amherst, Massachusetts Mansoor M. Amiji Department of Pharmaceutical Sciences Northeastern University Boston, Massachusetts Joseph M. Backer SibTech, Inc. Newington, Connecticut Marina V. Backer SibTech, Inc. Newington, Connecticut You Han Bae Department of Pharmaceutics and Pharmaceutical Chemistry University of Utah Salt Lake City, Utah Lajos P. Balogh Department of Radiation Medicine and Department of Cellular Stress and Cancer Biology Roswell Park Cancer Institute Buffalo, New York q 2006 by Taylor & Francis Group, LLC Rolf F. Barth Department of Pathology The Ohio State University Columbus, Ohio Reina Bendayan Department of Pharmaceutical Sciences University of Toronto Toronto, Ontario, Canada Tania Betancourt The University of Texas at Austin Austin, Texas D. Bhadra Department of Pharmaceutical Sciences Dr. H.S. Gour University Sagar, India S. Bhadra Department of Pharmaceutical Sciences Dr. H.S. Gour University Sagar, India Sangeeta N. Bhatia Harvard–MIT Division of Health Sciences and Technology Massachusetts Institute of Technology Cambridge, Massachusetts Sarathi V. Boddapati Department of Pharmaceutical Sciences Northeastern University Boston, Massachusetts Lisa Brannon-Peppas The University of Texas at Austin Austin, Texas Mark Butler Department of Chemical Engineering and Applied Chemistry University of Toronto Toronto, Ontario, Canada John C. Byrd Division of Hematology–Oncology NCI Comprehensive Cancer Center The Ohio State University Columbus, Ohio
Page 1: q 2006 by Taylor & Francis Group, L
Page 4 and 5: q 2006 by Taylor & Francis Group, L
Page 7 and 8: Foreword We are at the threshold of
Page 9 and 10: Preface With parallel breakthroughs
Page 11: Editor Dr. Mansoor M. Amiji receive
Page 15 and 16: Ji Hoon Jeong Department of Pharmac
Page 17 and 18: Jong-Sang Park Department of Chemis
Page 19 and 20: Table of Contents Section 1 Nanotec
Page 21 and 22: Chapter 21 Combined Cancer Therapy
Page 23 and 24: 1 CONTENT Introduction and Rational
Page 25 and 26: Introduction and Rationale for Nano
Page 31 and 32: 2 CONTENTS Passive Targeting of Sol
Page 33 and 34: Passive Targeting of Solid Tumors 1
Page 39 and 40: 3 CONTENTS Active Targeting Strateg
Page 41 and 42: Active Targeting Strategies in Canc
Page 63 and 64:
4 CONTENTS Pharmacokinetics of Nano
Page 65 and 66:
Pharmacokinetics of Nanocarrier-Med
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
5 CONTENTS Multifunctional Nanopart
Page 81 and 82:
Multifunctional Nanoparticles for C
Page 83 and 84:
Page 85 and 86:
(a) (b) 0.03 0.02 Δe 0.01 0.00 q 2
Page 87 and 88:
H 2 N N N NH 2 H CH 3 C HN O 5 HO C
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95:
Page 98 and 99:
78 6.8 Other Macromolecules Used fo
Page 100 and 101:
80 (EGF) and the mAb cetuximab (IMC
Page 102 and 103:
82 HO O HO O O O O O O H N S O H N
Page 104 and 105:
84 H 2N Cy5 Cy5 A B G5 G5 G5 Cy5 NH
Page 106 and 107:
86 synthon, a bifunctional carboran
Page 108 and 109:
88 O O H 4 6 8 NH 3 + Cl - 2- (CH 2
Page 110 and 111:
90 A per molecule of mAb was approx
Page 112 and 113:
92 in the cytoplasm, and had high c
Page 114 and 115:
94 in TF-PEG liposomes had a prolon
Page 116 and 117:
96 In conclusion, there is a pletho
Page 118 and 119:
98 Nanotechnology for Cancer Therap
Page 120 and 121:
100 Nanotechnology for Cancer Thera
Page 122 and 123:
Page 125 and 126:
7 CONTENTS Preclinical Characteriza
Page 127 and 128:
Preclinical Characterization of Eng
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
144 costly. The Critical Path Initi
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
150 At this point, and based on int
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
160 endothelial cells. 7-9 Anti-ang
Page 180 and 181:
162 TABLE 9.1 Some Ligands and Thei
Page 182 and 183:
164 Aminopeptidase A (APA) is a hom
Page 184 and 185:
166 cancer. 97 In tumor extract con
Page 186 and 187:
168 9.4 POLYMERIC CONJUGATES FOR AN
Page 188 and 189:
170 was significant inhibition of t
Page 190 and 191:
172 % ID/g (a) % ID/g (b) 16.000 14
Page 192 and 193:
174 conjugates of RGD4C and RGDfK p
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
186 of normal tissues to the drug.
Page 206 and 207:
188 greater selectivity toward tumo
Page 208 and 209:
Page 210 and 211:
192 side effects, and more convenie
Page 212 and 213:
Page 214 and 215:
196 to meet a number of challenges,
Page 216 and 217:
Page 219 and 220:
11 CONTENTS Noninvasive Visualizati
Page 221 and 222:
Noninvasive Visualization of In Viv
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
12 CONTENTS Polymeric Nanoparticles
Page 233 and 234:
Polymeric Nanoparticles for Tumor-T
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245:
Page 248 and 249:
232 discontinuous endothelium in th
Page 250 and 251:
234 immunogenicity, have encouraged
Page 252 and 253:
Page 254 and 255:
238 that PEGylated gelatin nanopart
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
244 above problem of delivery as we
Page 262 and 263:
246 Uptake (μg/mg cell protein) (a
Page 264 and 265:
248 Recently, He et al. have formul
Page 266 and 267:
Page 268 and 269:
252 15.1 CANCER THERAPY Cancer is d
Page 270 and 271:
254 15.2.1.1.2 Emulsion Polymerizat
Page 272 and 273:
256 15.2.1.3 Poly(Alkyl Cyanoacryla
Page 274 and 275:
258 The copolymer poly[aminopoly(et
Page 276 and 277:
260 The molecular weight difference
Page 278 and 279:
Page 280 and 281:
264 in delivering mitoxantrone to t
Page 282 and 283:
266 Golgi apparatus, histiocytes, m
Page 284 and 285:
268 of the adhesive composition has
Page 286 and 287:
270 nucleus nanoparticle P-gp (a) (
Page 288 and 289:
272 both the doxorubicin and the do
Page 290 and 291:
274 15.2.6.4 Drug Delivery to Brain
Page 292 and 293:
276 formation of the doxorubicin-gl
Page 294 and 295:
278 by Loewe et al. 186 using NBCA
Page 296 and 297:
280 15.3 CONCLUSIONS Drug delivery
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
292 of molecules for targeted deliv
Page 310 and 311:
294 case of isolating DNA aptamers,
Page 312 and 313:
296 16.2.3.6 Cytotoxic T-Cell Antig
Page 314 and 315:
298 16.3.1.2 Polymers for Synthesis
Page 316 and 317:
300 eliminate the need for subseque
Page 318 and 319:
302 3' 5' X 3' 3' X Y 5' 5' X X apt
Page 320 and 321:
304 In addition to small molecule a
Page 322 and 323:
306 16.6 CONCLUSION Bioconjugates c
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 331 and 332:
17 CONTENTS Polymeric Micelles for
Page 333 and 334:
Polymeric Micelles for Formulation
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369:
Page 372 and 373:
358 18.1 INTRODUCTION Polymeric mic
Page 374 and 375:
360 (a) (b) R' NH 2 R' NH 2 + R' NH
Page 376 and 377:
362 18.3.1 DIALYSIS METHOD In this
Page 378 and 379:
364 O O PEO-b-P(Asp)-DOX CH3 O CH2
Page 380 and 381:
366 PEO-b -PHSA PEO-b -PBLG PEO-b -
Page 382 and 383:
368 stable and entirely elute as mi
Page 384 and 385:
370 showed similar side effects to
Page 386 and 387:
372 but polymeric micellar formulat
Page 388 and 389:
374 H 2 N H 2 N N H N O N N FOL H N
Page 390 and 391:
376 P(L-Lys)s were further studied
Page 392 and 393:
Page 394 and 395:
Page 396 and 397:
Page 399 and 400:
19 CONTENTS Hydrotropic Polymer Mic
Page 401 and 402:
Hydrotropic Polymer Micelles for Ca
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
20 CONTENTS Tumor-Targeted Delivery
Page 425 and 426:
Tumor-Targeted Delivery of Sparingl
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Page 435 and 436:
21 CONTENTS Combined Cancer Therapy
Page 437 and 438:
Combined Cancer Therapy by Micellar
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Page 449 and 450:
Page 451 and 452:
Page 453 and 454:
Page 455:
Page 458 and 459:
444 release have been attempted, in
Page 460 and 461:
446 day at room temperature. The po
Page 462 and 463:
448 Intensity (%) (a) 25 20 15 10 5
Page 464 and 465:
450 CMC (μg/ml) 4.0 3.5 3.0 2.5 2.
Page 466 and 467:
452 Cell viability (%) by MTT assay
Page 468 and 469:
454 body weight in experimental gro
Page 470 and 471:
456 Cell Viability (%) by MTT assay
Page 472 and 473:
458 Cell viability (%) by MTT assay
Page 474 and 475:
460 Total DOX (%) in organs This, c
Page 476 and 477:
Page 478 and 479:
Page 480 and 481:
466 Hydrophobic core Hydrated shell
Page 482 and 483:
468 Percentage of cell uptake (a) 1
Page 484 and 485:
470 MRI is another imaging modality
Page 486 and 487:
472 4 nm SPIO DSPE-PEG5k 4 nm SPIO
Page 488 and 489:
474 ACKNOWLEDGMENTS This work was s
Page 491 and 492:
24 CONTENTS Targeted Antisense Olig
Page 493 and 494:
Targeted Antisense Oligonucleotide
Page 495 and 496:
Page 497 and 498:
Page 499 and 500:
Page 501 and 502:
25 CONTENTS Dendrimers as Drug and
Page 503 and 504:
Dendrimers as Drug and Gene Deliver
Page 505 and 506:
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
Page 517 and 518:
Page 519 and 520:
Page 521 and 522:
26 CONTENTS Dendritic Nanostructure
Page 523 and 524:
Dendritic Nanostructures for Cancer
Page 525 and 526:
Page 527 and 528:
Page 529 and 530:
Page 531 and 532:
Page 533:
Page 536 and 537:
524 invasiveness, undifferentiated
Page 538 and 539:
526 ligand Drug Drug Nanosphere Nan
Page 540 and 541:
528 PEG has polyether backbone that
Page 542 and 543:
Page 544 and 545:
532 genomic revolution progresses,
Page 546 and 547:
534 opportunities and solutions to
Page 548 and 549:
536 FIGURE 27.3 Chemical structural
Page 550 and 551:
538 Water-soluble dendritic unimole
Page 552 and 553:
540 Luo et al. (2002) demonstrated
Page 554 and 555:
Page 556 and 557:
544 IgE-receptor complexes, whereas
Page 558 and 559:
Page 560 and 561:
Page 563 and 564:
28 CONTENTS Dendrimer Nanocomposite
Page 565 and 566:
Dendrimer Nanocomposites for Cancer
Page 567 and 568:
Page 569 and 570:
Page 571 and 572:
Page 573 and 574:
Page 575 and 576:
Page 577 and 578:
Page 579 and 580:
Page 581 and 582:
Page 583 and 584:
Page 585 and 586:
Page 587 and 588:
Page 589 and 590:
Page 591 and 592:
Page 593 and 594:
Page 595 and 596:
Page 597 and 598:
Page 599 and 600:
Page 601 and 602:
Page 603 and 604:
Page 605 and 606:
29 CONTENTS Applications of Liposom
Page 607 and 608:
Applications of Liposomal Drug Deli
Page 609 and 610:
Page 611 and 612:
Page 613 and 614:
Page 615 and 616:
Page 617 and 618:
Page 619 and 620:
Page 621:
Page 624 and 625:
Page 626 and 627:
Page 628 and 629:
618 In many instances, the use of n
Page 630 and 631:
620 weight polymers to the liposome
Page 632 and 633:
Page 634 and 635:
624 uptake by healthy organ tissues
Page 636 and 637:
Page 639 and 640:
31 CONTENTS Cell Penetrating Peptid
Page 641 and 642:
CPP-Modified Liposomal Nanocarriers
Page 643 and 644:
Page 645 and 646:
Page 647 and 648:
Page 649 and 650:
Page 651:
Page 654 and 655:
644 Allen 1998), serum proteins (Br
Page 656 and 657:
646 cell; partial denuding of the e
Page 658 and 659:
648 to distinct, but often overlapp
Page 660 and 661:
650 TABLE 32.3 Integrin Receptors a
Page 662 and 663:
652 Basement Membrane Carcinoma Inv
Page 664 and 665:
654 YIGSR RGD distearoylphosphatidy
Page 666 and 667:
656 FIGURE 32.10 (See color insert
Page 668 and 669:
Page 670 and 671:
Page 673 and 674:
33 CONTENTS Folate Receptor-Targete
Page 675 and 676:
Folate Receptor-Targeted Liposomes
Page 677 and 678:
Page 679 and 680:
Page 681 and 682:
Page 683 and 684:
Page 685:
Page 688 and 689:
Page 690 and 691:
Page 692 and 693:
682 FIGURE 34.2 (a) A new paradigm
Page 694 and 695:
684 34.2.2 GETTING THE NANOCAPSULES
Page 696 and 697:
686 Expansion modulus K A mN/m 4000
Page 698 and 699:
688 (x) 90 min after injection' 1 m
Page 700 and 701:
Page 702 and 703:
692 Drug FIGURE 34.10 A tentative l
Page 704 and 705:
694 Thermal sensitive liposomes (TS
Page 706 and 707:
696 (a) (b) (c) 5 μm 1 μm 40 μm
Page 708 and 709:
698 - SO2 - SO2 - SO2 NBD - NBD - -
Page 710 and 711:
700 melting grain boundaries, formi
Page 712 and 713:
702 Percent of DOX released 100 90
Page 714 and 715:
704 Relative tumour volume (V/Vo )
Page 716 and 717:
706 (a) 0.6 LTSL-HT LTSL-DOX-HT LTS
Page 718 and 719:
708 differences in the levels of hy
Page 720 and 721:
710 trials, and preliminary indicat
Page 722 and 723:
712 encapsulated liposomal contents
Page 724 and 725:
Page 726 and 727:
Page 728 and 729:
Page 731 and 732:
35 CONTENTS Nanoemulsion Formulatio
Page 733 and 734:
Nanoemulsion Formulations for Tumor
Page 735 and 736:
Page 737 and 738:
Page 739 and 740:
Page 741 and 742:
Page 743 and 744:
Page 745 and 746:
Page 747:
Page 750 and 751:
742 36.5.5 Delivery of Chemosensiti
Page 752 and 753:
744 TABLE 36.1a Structures of Lipid
Page 754 and 755:
746 TABLE 36.3 Categories of Solid
Page 756 and 757:
748 Poly(ethylene oxide) (PEO) chai
Page 758 and 759:
750 FIGURE 36.3 Transmission electr
Page 760 and 761:
752 Cold homogenization method Melt
Page 762 and 763:
754 release kinetics of SLN and NLC
Page 764 and 765:
756 for lyophilization, the reconst
Page 766 and 767:
758 related work are listed in Tabl
Page 768 and 769:
760 improve its water solubility an
Page 770 and 771:
762 formulations. These include dox
Page 772 and 773:
764 36.5.5 DELIVERY OF CHEMOSENSITI
Page 774 and 775:
766 In other words, synergistic eff
Page 776 and 777:
768 FIGURE 36.15 Fluoroescence micr
Page 778 and 779:
770 because of the presence of the
Page 780 and 781:
Page 782 and 783:
Page 784 and 785:
Page 786 and 787:
778 Phospholipid Unesterified chole
Page 788 and 789:
Page 790 and 791:
782 via receptor-mediated mechanism
Page 792 and 793:
Page 795 and 796:
38 CONTENTS DQAsomes as Mitochondri
Page 797 and 798:
DQAsomes as Mitochondria-Targeted N
Page 799 and 800:
Page 801 and 802:
Page 803 and 804:
Page 805 and 806:
Page 807 and 808:
Page 809 and 810:
Page 811:
Section 1 Nanotechnology and Cancer
Page 815:
Section 3 Polymeric Nanoparticles q
Page 819:
Section 5 Dendritic Nanocarriers q
Page 823:
Section 7 Other Lipid Nanostructure
show all

q 2006 by Taylor & Francis Group, LLC - Developers

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?